Tag Archives: CTRV

ContraVir Pharmaceuticals Inc Receives a Buy from Maxim Group

Maxim Group analyst Gabrielle Zhou reiterated a Buy rating on ContraVir Pharmaceuticals Inc (NASDAQ: CTRV) today and set a price target of $4. The company’s shares opened today at $1.68. Zhou observed: “ContraVir announced new data presentation of TXL (Tenofovir

ContraVir Pharmaceuticals Inc Gets a Buy from Noble Financial

Noble Financial analyst Mark Jordan reiterated a Buy rating on ContraVir Pharmaceuticals Inc (NASDAQ: CTRV) on April 5. The company’s shares closed yesterday at $1.56. According to TipRanks.com, Jordan is a 3-star analyst with an average return of 2.1% and

ContraVir Pharmaceuticals Inc Gets a Buy from Maxim Group

Maxim Group analyst Gabrielle Zhou reiterated a Buy rating on ContraVir Pharmaceuticals Inc (NASDAQ: CTRV) today and set a price target of $4. The company’s shares closed yesterday at $1.78. Zhou commented: “ContraVir announced preclinical data from new studies of

ContraVir Pharmaceuticals Receives a Buy from Maxim Group

According to The Fly, maxim Group analyst Jason Kolbert reiterated a Buy rating on ContraVir Pharmaceuticals (NASDAQ: CTRV) today and set a price target of $4. The company’s shares opened today at $0.97, close to its 52-week low of $0.76.

Maxim Group Thinks ContraVir Pharmaceuticals’ Stock is Going to Recover

According to The Fly, maxim Group analyst Jason Kolbert reiterated a Buy rating on ContraVir Pharmaceuticals (NASDAQ: CTRV) today and set a price target of $4. The company’s shares opened today at $0.95, close to its 52-week low of $0.76.

Maxim Group Thinks ContraVir Pharmaceuticals’ Stock is Going to Recover

According to The Fly, in a report released yesterday, Jason Kolbert from Maxim Group reiterated a Buy rating on ContraVir Pharmaceuticals (NASDAQ: CTRV), with a price target of $4. The company’s shares opened today at $0.98, close to its 52-week